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Preoperative Underweight Patients with Upper Tract Urothelial 
Carcinoma Survive Less after Radical Nephroureterectomy
The prognostic impact of body mass index (BMI) in patients with upper tract urothelial 
carcinoma (UTUC) is an ongoing debate. Our study aimed to investigate the prognostic role 
of BMI in patients treated with radical nephroureterectomy (RNU) for UTUC from a multi-
institutional Korean collaboration. We retrospectively reviewed data from 440 patients 
who underwent RNU for UTUC at four institutions in Korea. To avoid biasing the survival 
estimates, patients who had previous or concomitant muscle-invasive bladder tumors were 
excluded. BMI was categorized into approximate quartiles with the lowest quartile 
assigned to the reference group. Kaplan-Meier and multivariate Cox regression analyses 
were performed to assess the influence of BMI on survival. The lower quartile BMI group 
showed significantly increased overall mortality (OM) and cancer specific mortality (CSM) 
compared to the 25%-50% quartiles and upper quartile BMI groups. Kaplan-Meier 
estimates showed similar results. Based on multivariate Cox regression analysis, 
preoperative BMI as a continuous variable was an independent predictor for OM and CSM. 
In conclusion, preoperative underweight patients with UTUC in Korea survive less after 
RNU. Preoperative BMI may provide additional prognostic information to establish risk 
factors. 
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INTRODUCTION
Upper tract urothelial carcinoma (UTUC) is a relatively rare neo­
plasm and accounts for 5%­6% of all urothelial tumors. Approx­
imately 20%­40% of patients initially present with locally advan­
ced disease and lymph node metastases at the time of diagno­
sis (1­4). Radical nephroureterectomy (RNU) is the surgical stan­
dard of care for the treatment of patients with UTUC (5). How­
ever, contemporary oncologic outcomes remain poor because 
of the high risk of systemic recurrence following surgery (6). The 
5­yr survival rates for patients classified with pT2 and pT3 stage 
disease are 73% and 40%, respectively, and the median survival 
for patients with T4 stage disease is estimated to be 6 months (7, 
8). Tumor stage, grade, lymph node status, lymphovascular in­
vasion (LVI), multifocality, and histologic tumor necrosis are 
pathological variables identified as prognostic factors in UTUC 
following RNU (9, 10). More accurate predictors of clinical out­
comes could possibly lead to better identification and counsel­
ing for patients with potentially unfavorable outcomes who may 
benefit from adjuvant chemotherapy (11­13). Currently, knowl­
edge of preoperatively assessable prognostic factors in UTUC is 
still limited. Preoperative prognostic factors including patients’ 
body composition, age, gender, and previous bladder cancer 
history may offer the opportunity for more convenient stratifi­
cation prior to operation, compared to conventional pathologi­
cal risk factors (14). The relationship among obesity, cancer risk, 
and prognostic influence of body mass index (BMI) have been 
reported for numerous malignancies (15­17), but the impact of 
BMI on the prognosis of patients with UTUC is still poorly de­
fined. Previous studies revealed contradictory results regarding 
the prognostic value of BMI in patients with UTUC after RNU. 
Most studies on Western cohort have shown that higher BMI is 
associated with worse survival outcomes (18, 19), whereas stud­
ies of Asian population noted that increased BMI was an inde­
pendent predictor for favorable survival (14, 20). Asian popula­
tions have a higher percentage of body fat for a given BMI than 
Caucasians and the Asia Cohort Consortium proposed a new 
BMI cutoff for public health action in Asia (21). Difference in 
body composition profiles and inclusion criteria between eth­
nic groups may explain these discrepancies. However, only two 
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Asian population studies examining the effect of BMI on the 
oncological outcomes after RNU have thus far been reported 
and limited by its small sample size. Moreover, no study in Ko­
rea has been reported yet. Therefore, we investigated the prog­
nostic role of BMI in patients treated with RNU for UTUC from 
a large, multi­institutional Korean collaboration. 
MATERIALS AND METHODS
Patients
After obtaining institutional review board (IRB) approval, a da­
tabase of 505 patients with UTUC who underwent either open 
or laparoscopic RNU between 2001 and 2013 at four academic 
centers was reviewed. The database listed patient characteris­
tics including age, gender, BMI, history of bladder cancer, pre­
operative American Society of Anesthesiologists Physical Status 
(ASA­PS) score, surgical approach (open vs. laparoscopic), tu­
mor pathology (stage, grade, lymph node status, and lympho­
vascular invasion), tumor necrosis, concomitant carcinoma in 
situ, tumor location, use of adjuvant chemotherapy, prior en­
doscopic therapy, unifocal or multifocal disease (UTUC multi­
focality was defined as the synchronous presence of multiple 
tumors in the renal pelvis or ureter), disease recurrence, mor­
tality from urothelial carcinoma. All of the patients had com­
plete follow­up data available and were considered for the anal­
ysis. A computerized databank was generated for the data trans­
fer. After combining the data sets, reports were generated for 
each variable to identify data inconsistencies and other data in­
tegrity problems. Prior to final analysis, the database was fro­
zen, and the final data set was produced for the current analy­
sis. To avoid biasing the survival estimates, patients who had 
previous or concomitant muscle­invasive bladder tumors treat­
ed by cystectomy were excluded. Patients with distant metasta­
sis at diagnosis and those who received neoadjuvant therapies 
were also excluded and 440 patients remained eligible.
 Surgery was performed according to the standard criteria for 
RNU: extrafascial dissection of the kidney with the entire length 
of the ureter and the adjacent segment of the bladder cuff. The 
hilar and regional lymph nodes adjacent to the ipsilateral great 
vessel were generally resected if they were palpable intraopera­
tively or enlarged during preoperative axial imaging. All surgi­
cal specimens were processed according to the standard patho­
logical procedures at each institution. The tumor was assessed 
according to the 2002 American Joint Committee on Cancer/
Union Internationale Contre le Cancer TNM classification. Tu­
mor grading was assessed using the 1998 World Health Organi­
zation/International Society of Urologic Pathology consensus 
classification. 
 Each patient was monitored according to the standard guide­
lines. In general, patients were evaluated every 3­4 months for 
the 1st year following nephroureterectomy, every 6 months from 
the second through the 5th year, and annually thereafter. Fol­
low­up consisted of a history taking, physical examination, rou­
tine blood and serum chemistry laboratory work, urine cytolo­
gy, chest radiography, cystoscopic evaluation of the urinary bla­
dder, and radiographic evaluation of the upper urinary tract. 
Bone scans, chest computed tomography, or magnetic reso­
nance imaging was performed when clinically indicated.
 In this study, disease recurrence was defined as a locoregion­
al recurrence or a new distant metastasis based on clinical and 
radiographic findings. Recurrence­free survival was defined as 
the period between surgery and the detection of recurrence, 
distant metastasis, or the study’s endpoint. Time to cancer­spe­
cific survival was calculated as the time from surgery to the date 
of cancer­attributable mortality. 
Statistical analysis
Preoperative BMI was classified by quartiles of the range: quar­
tile 1, < 21.7 kg/m2; quartile 2, 21.7­23.7 kg/m2; quartile 3, 23.8­ 
25.7 kg/m2; quartile 4, ≥ 25.8 kg/m2. Continuous variables are 
shown as the median and interquartile range (IQR). Differenc­
es in variables with continuous distributions across dichoto­
mous categories were assessed using ANOVA. The Fisher’s ex­
act and chi­square tests were used to evaluate the association 
between categorical variables. The statistical endpoints for our 
analysis were recurrence­free, cancer­specific, and overall sur­
vival of patients. Survival analyses were conducted according to 
the Kaplan­Meier method and survival characteristics were 
compared using the log­rank test. Univariate and multivariate 
survival analyses were performed using the Cox proportional 
hazard regression model. Statistical significance was considered 
to be P < 0.05 and all reported P values are 2­sided. Analyses 
were performed using SPSS 20.0 software (SPSS Inc., Chicago, 
IL, USA).
Ethics statement
The study was carried out in agreement with the applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. The institutional re­
view board of Yonsei University College of Medicine approved 
this study protocol (Approval number: 4­2014­0634). Informed 
consent was waived by the board.
RESULTS
Clinicopathological characteristics according to BMI 
categories 
Table 1 lists the demographics and clinicopathological charac­
teristics of the study population categorized by preoperative 
BMI quartiles. There were no significant differences among the 
subsets of patients in terms of clinicopathological characteris­
tics including age, gender, history of previous or concomitant 
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bladder cancer, ASA­PS score, pathologic stage, pathologic grade, 
lymph node status, lymphovascular invasion, surgical margin 
status, concomitant carcinoma in situ, tumor location, adjuvant 
chemotherapy, or multifocality (all P > 0.05).
Locoregional recurrence/distant metastasis by BMI 
categories 
The median follow­up period of the study cohort was 31 months 
(IQR 15 to 57 months). Overall, 111 patients (25.2%) experienc­
ed locoregional recurrence/distant metastasis. The recurrence/
metastatic free survival at 3 and 5 yr were 72% and 67%, respec­
tively. Compared to the lower quartile BMI group, the 25%­50% 
quartiles was associated with approximately 50% reduced odds 
of locoregional recurrence/distant metastasis (Table 2). Kaplan­
Meier analyses did not exhibit significantly different recurrence 
free survival between BMI grouping (Figure not shown).
Table 1. Comparison of the demographics and clinicopathological characteristics according to BMI subgroup
Parameters
BMI quartiles
0%-25% 
( < 21.7 kg/m2)
25%-50% 
(21.7-23.7 kg/m2)
50%-75% 
(23.8-25.7 kg/m2)
75%-100% 
( ≥ 25.8 kg/m2)
P value
No. of patients 110 110 110 110
Age (yr, mean ± SD) 68.0 ± 11.4 65.3 ± 10.8 65.6 ± 10.0 65.5 ± 10.3 0.182*
ASA-PS score
1
2
3
31 (25.9)
59 (56.2)
15 (14.3)
29 (28.7)
67 (66.3)
5 (5.0)
32 (31.4)
65 (63.7)
5 (4.9)
26 (24.5)
69 (65.1)
11 (10.4)
0.153†
Smoking history (%) 41 (37.3) 25 (22.7) 34 (30.9) 25 (22.7) 0.066†
Gender (%)
Male
Female
80 (72.7)
30 (27.3)
78 (70.9)
32 (29.1)
75 (68.2)
35 (31.8)
72 (65.5)
38 (34.5)
0.666†
Previous or concomitant NMIBC (%) 18 (16.4) 19 (17.3) 30 (27.3) 21 (19.1) 0.164†
Tumor location (%)
Renal pelvis
Ureter
Both
46 (41.8)
49 (44.5)
15 (13.6)
38 (34.5)
55 (50.0)
17 (15.5)
41 (37.3)
51 (46.4)
18 (16.4)
34 (30.9)
64 (58.2)
12 (10.9)
0.456†
Pathologic T stage (%)
Tis 
Ta 
T1 
T2 
T3 
T4 
1 (0.9)
3 (2.7)
34 (30.9)
29 (26.4)
40 (36.4)
3 (2.7)
2 (1.8)
6 (5.5)
34 (30.9)
21 (19.1)
46 (41.8)
1 (0.9)
2 (1.8)
5 (4.5)
32 (29.1)
29 (26.4)
41 (37.3)
1 (0.9)
3 (2.7)
9 (8.2)
35 (31.8)
32 (29.1)
28 (25.5)
3 (2.7)
0.578†
Pathologic N stage (%)
Nx 
N0 
N1-2 
46 (41.8)
59 (53.6)
5 (4.5)
55 (50.0)
49 (44.5)
6 (5.5)
50 (45.5)
54 (49.1)
6 (5.5)
61 (55.5)
46 (41.8)
3 (2.7)
0.486†
Tumor grade (%)
Low
High
23 (20.9)
87 (79.1)
25 (22.7)
85 (77.3)
30 (27.3)
80 (72.7)
32 (29.1)
78 (70.9)
0.463†
Multiplicity (%) 30 (27.3) 32 (29.1) 27 (24.5) 22 (20.0) 0.434†
Concomitant CIS (%) 4 (4.6) 8 (8.4) 7 (7.6) 11 (11.5) 0.403†
Lymphovascular invasion (%) 19 (17.3) 20 (18.2) 19 (17.3) 18 (16.4) 0.988†
Positive surgical margin (%) 8 (7.3) 8 (7.3) 3 (1.8) 5 (4.5) 0.209†
Adjuvant chemotherapy 23 (20.9) 21 (19.1) 22 (20.0) 12 (10.9) 0.187†
P value was based on the *ANOVA and †Fisher exact test. BMI, body mass index; SD, standard deviation; BC, bladder cancer; ASA-PS, American Society of Anesthesiologists 
Physical Status; NMIBC, non-muscle invasive bladder cancer; CIS, carcinoma in situ. 
Table 2. Oncologic outcomes among the BMI quartiles in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
BMI quartiles† Recurrence (%) OR (95%, CI)* P CSM (%) OR (95%, CI)* P OM (%) OR (95%, CI)* P
1 35 (31.8) 1 34 (30.9) 1 29 (26.4) 1
2 22 (20.0) 0.479 (0.243-0.942) 0.033 15 (13.6) 0.327 (0.159-0.674) 0.002 11 (10.0) 0.282 (0.126-0.630) 0.002
3 30 (27.3) 0.757 (0.398-1.441) 0.397 22 (20.0) 0.566 (0.294-1.090) 0.089 17 (15.5) 0.521 (0.255-1.067) 0.075
4 24 (21.8) 0.711 (0.367-1.376) 0.311 16 (14.5) 0.385 (0.187-0.795) 0.010 12 (10.9) 0.358 (0.160-0.799) 0.012
*ORs were calculated by unconditional logistic regression analysis and adjusted for pathologic stage and grade; †Preoperative BMI was classified by quartiles of the range: quar-
tile 1, < 21.7 kg/m2; quartile 2, 21.7-23.7 kg/m2; quartile 3, 23.8-25.7 kg/m2; quartile 4, ≥ 25.8 kg/m2. BMI, body mass index; CSM, cancer specific mortality; OM, overall 
mortality; CI, confidence interval; OR, odds ratio.
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Fig. 1. Kaplan-Meier survival curves. (A) Overall survival. (B) Disease-specific survival categorized by BMI in patients with upper tract urothelial carcinoma following radical nephro-
ureterectomy. 
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Table 3. Univariate and multivariate Cox regression models for the prediction of overall mortality in patients treated with radical nephroureterectomy for upper tract urothelial 
carcinoma
Variables
Univariate analysis Multivariate analysis
HR (95%, CI) P value HR (95%, CI) P value
Age (continuous) 1.027 (1.004-1.050) 0.021 1.019 (0.994-1.045) 0.139
Gender (female) 1.000 (0.635-1.576) 1.000
ASA-PS score ( ≥ 3) 2.084 (1.150-3.776) 0.015 1.981 (1.057-3.711) 0.033
BMI (continuous) 0.914 (0.853-0.979) 0.010 0.922 (0.853-0.998) 0.045
Smoking history (yes) 0.994 (0.612-1.614) 0.980
Tumor size (continuous) 1.009 (1.003-1.015) 0.004 1.005 (0.998-1.012) 0.199
Multiplicity (yes) 1.590 (1.028-2.458) 0.037 1.665 (0.939-2.952) 0.081
Pathologic T stage ( ≥ T3) and/or N stage (N1-2) 3.025 (1.734-5.278) < 0.001 1.964 (1.009-3.824) 0.047
Grade (high) 2.723 (1.478-5.018) 0.001 1.774 (0.861-3.658) 0.120
Concomitant CIS (yes) 0.757 (0.275-2.085) 0.591
Lymphovascular invasion (yes) 3.198 (2.061-4.960) < 0.001 2.400 (1.469-3.921) < 0.001
Margin status (positive surgical margin) 4.178 (2.256-7.738) < 0.001 2.478 (1.261-4.871) 0.008
Adjuvant chemotherapy (yes) 1.799 (1.108-2.921) 0.017 1.407 (0.776-2.550) 0.261
HR, hazard ratio; CI, confidence interval; ASA-PS, American Society of Anesthesiologists Physical Status; BMI, body mass index; CIS, carcinoma in situ.
Overall mortality and cancer specific mortality by BMI 
categories 
During follow up, 69 patients (15.7%) died of UTUC. The cancer 
specific survival (CSS) at 3 and 5 yr was 82% and 76%, respec­
tively. The 25%­50% quartiles and upper quartile BMI groups 
were associated with approximately 60% reduced odds of over­
all mortality (OM) and cancer specific mortality (CSM) than the 
lower quartile BMI group following adjustment for pathologic T 
stage and pathologic grade (Table 2). Kaplan­Meier estimates 
showed that the lower quartile BMI group had poorer overall 
survival (OS) and CSS compared to the middle two quartiles 
and the upper quartile BMI groups (Fig. 1). Using multivariate 
Cox regression analysis, preoperative BMI as a continuous vari­
ables (HR, 0.922; CI, 0.853­0.998, P = 0.045), ASA­PS score (≥ 3) 
(P = 0.033), locally advanced stage or node positive state (P =  
0.047), lymphovascular invasion (P < 0.001), and margin status 
(P = 0.008) were independent predictors of OM (Table 3). On 
the other hand, preoperative BMI as a continuous variables (HR, 
0.906; CI, 0.830­0.990, P = 0.028), ASA­PS score (≥ 3) (P = 0.025), 
locally advanced stage or node positive state (P = 0.027), lym­
phovascular invasion (P < 0.001), surgical margin (P = 0.010) 
were independent predictors of CSM (Table 4). 
DISCUSSION
The current study investigated the prognostic role of BMI in a 
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large, multi­institutional cohort of patients treated with RNU 
for UTUC. We categorized the patients’ cohorts into quartiles 
rather than using established BMI cut­off points, and demon­
strated that the preoperative BMI offers additional prognostic 
information. 
 Numerous studies have detected a significant association be­
tween preoperative BMI and cancer­susceptibility or aggressive­
ness in several hormone­related cancers, such as breast and en­
dometrial cancer (22, 23). BMI strongly correlates with densi­
tometry estimates of body fat composition in adults, and excess 
body fat is associated with increased insulin, which increases in­
sulin­like growth factor­I (IGF­I). IGF­I stimulates cell prolifera­
tion and suppresses apoptosis (24, 25). Excess body fat is also as­
sociated with systemic inflammation. Adipose tissue produces a 
variety of inflammatory factors, including leptin, adiponectin, 
and cytokines (26, 27). It is increasingly apparent that cancer 
progression depends on a complex interaction between the tu­
mor and host inflammatory responses. On the other hand, there 
is a paucity of data on the influences of BMI in hormone­inde­
pendent cancers such as urothelial carcinoma of the upper or 
lower urinary tract. There is no doubt that obesity strongly corre­
lates with perioperative complications and morbidity or mortal­
ity; however, little is known about the prognostic value of BMI in 
patients with UTUC after radical surgery (28). Previous studies 
revealed contradictory prognostic outcomes associated with 
BMI in UTUC patients. Ehdaie et al. (18) showed that increased 
BMI adversely impacts oncological outcomes in pati ents with 
UTUC. They found a 37% difference in both 5­yr disease­free 
survival and CSS rates between patients with BMI ≥ 30 kg/m2 
(49%, 47%) and patients with BMI < 25 kg/m2 (86%, 84%). They 
also found that patients with a higher body mass index were 
more likely to have infiltrative architecture and lymphovascular 
invasion. In our cohort, none of clinicopathologic variables 
shows interesting differences between BMI quartiles. Regard to 
locoregional recurrence/distant metastasis, the 25%­50% quar­
tile group have an approximately 50% reduced odds of locore­
gional recurrence/distant metastasis compared to the lower 
quartile BMI group, however, there was no significant differenc­
es among other subsets of patients. Thus we could not sure the 
potential association between BMI and aggressive tumor char­
acteristics. A Canadian multicenter collaboration study reported 
that patients with higher BMI (BMI ≥ 30 kg/m2) had worse RFS 
in patients undergoing RNU (1). However, they did not found 
any significant differences in OS or CSS among subsets of pa­
tients (BMI < 25, 25 ≤ BMI < 30, and BMI ≥ 30 kg/m2). In con­
trast, using a cohort of 103 Japanese UTUC patients, Inamoto et 
al. (14) employed original BMI cut­off (22 kg/m2) and showed 
that increased BMI (BMI ≥ 22 kg/m2) was an independent pre­
dictor for favorable OS and CSS. More recently, Liu et al. (20) an­
alyzed single center data for 236 Chinese UTUC patients. In this 
study, the mean CSS time was 42.7 months for underweight pa­
tients, 55.1 months for normal patients and 61.2 months for obe­
sity patients. They also demonstrated that a preoperative under­
weight was an independent predictor of unfavorable survival in 
patients with UTUC. They postulated three hypotheses to explain 
the improved outcomes for obese patients, including a functional 
barrier, increased energy sources, and multiple hormonal, en­
docrine, or nutritional factors. Although our data was similar to 
previous Asian cohort studies, it is hard to direct comparison of 
prognostic influence of BMI among stu dies because we did not 
use the established BMI criteria for Asi ans, issued by the Asia Co­
hort Consortium. Because there were only 16 patients (4% of to­
tal cohort) with underweight defined by Asia Cohort Consor­
tium (BMI lower than 18.5 kg/m2) in our cohort, we categorized 
the patients into approximate quartiles instead of using estab­
lished BMI cut­off points. By the definition of the Asia Cohort 
Consortium, preoperative underweight may overlap with tumor 
cachexia (29). Tumor cachexia has long been postulated to be a 
Table 4. Univariate and multivariate Cox regression models for the prediction of cancer specific mortality in patients treated with radical nephroureterectomy for upper tract 
urothelial carcinoma
Variables
Univariate analysis Multivariate analysis
HR (95%, CI) P value HR (95%, CI) P value
Age (continuous) 1.015 (0.991-1.040) 0.227
Gender (female) 1.192 (0.726-1.956) 0.487
ASA-PS score ( ≥ 3) 2.069 (1.051-4.071) 0.035 2.251 (1.107-4.579) 0.025
BMI (continuous) 0.905 (0.838-0.977) 0.011 0.906 (0.830-0.990) 0.028
Smoking history (yes) 0.788 (0.444-1.397) 0.414
Tumor size (continuous) 1.008 (1.001-1.015) 0.021 1.006 (0.998-1.014) 0.143
Multiplicity (yes) 1.566 (0.958-2.559) 0.074
Pathologic T stage ( ≥ T3) and/or N stage (N1-2) 4.859 (2.325-10.154) < 0.001 2.789 (1.125-6.914) 0.027
Grade (high) 4.385 (1.895-10.146) 0.001 2.720 (0.933-7.928) 0.067
Concomitant CIS (yes) 0.706 (0.220-2.269) 0.559
Lymphovascular invasion (yes) 4.176 (2.588-6.737) < 0.001 3.097 (1.810-5.297) < 0.001
Margin status (positive surgical margin) 4.559 (2.383-8.721) < 0.001 2.530 (1.246-5.138) 0.010
Adjuvant chemotherapy (yes) 2.355 (1.409-3.937) 0.001 1.697 (0.904-3.187) 0.100
HR, hazard ratio; CI, confidence interval; ASA-PS, American Society of Anesthesiologists Physical Status; BMI, body mass index; CIS, carcinoma in situ.
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key determinant of cancer­related death. However, this hypothesis 
is applicable only for small part of the whole, actually, under­
weight defined by WHO criterion for the Asia Pa cific Region ac­
counts for approximately 4% of whole population, and 2.5% of 
men over thirties in Korea (30). In our preliminary analyses, op­
timal BMI cut­off value which gave optimal sensitivity and speci­
ficity for cancer specific mortality in patients treated with RNU for 
UTUC was 21.61 kg/m2 (data not shown). To determine the opti­
mal BMI cut­off point can stratify patients with UTUC after RNU 
into unfavorable or favorable prognostic groups, additional col­
laboration studies in other populations are inevitable. 
 Our study had several inherent weaknesses. First, standard­
ization of surgical techniques or practice guidelines such as ad­
juvant chemotherapy and follow­up protocols was impossible 
because of the multi­institutional and retrospective nature of 
the study. Relatively short periods of follow­up and its retrospec­
tive nature also warrant consideration. In addition, databank 
from four institutions did not handle the weight change. Weight 
loss has been shown to be an independent prognostic indicator 
of decreased survival in cancer patients. However, our study co­
hort has a relatively localized stage and metastatic cancer pati­
ents with severe cachexia were excluded. 
 In conclusion, preoperative underweight patients with UTUC 
in Korea survive less after RNU. Current high volume, multi­
center study reconfirmed the adverse prognostic impact of pre­
operative underweight in Korean UTUC patients following RNU. 
International collaboration studies are needed to give an account 
for ethical contradictory results between Asia and the West.
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